

University of Texas Rio Grande Valley

ScholarWorks @ UTRGV

---

School of Medicine Publications and  
Presentations

School of Medicine

---

8-2019

## Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes

Gladys E. Maestre

Follow this and additional works at: [https://scholarworks.utrgv.edu/som\\_pub](https://scholarworks.utrgv.edu/som_pub)



Part of the [Diseases Commons](#), and the [Neurology Commons](#)

---

### Recommended Citation

Maestre, Gladys E., "Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes" (2019). *School of Medicine Publications and Presentations*. 24.  
[https://scholarworks.utrgv.edu/som\\_pub/24](https://scholarworks.utrgv.edu/som_pub/24)

This Article is brought to you for free and open access by the School of Medicine at ScholarWorks @ UTRGV. It has been accepted for inclusion in School of Medicine Publications and Presentations by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact [justin.white@utrgv.edu](mailto:justin.white@utrgv.edu), [william.flores01@utrgv.edu](mailto:william.flores01@utrgv.edu).

# Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes

Wen-Yi Yang, MD, PhD; Jesus D. Melgarejo, MD; Lutgarde Thijs, MSc; Zhen-Yu Zhang, MD, PhD; José Boggia, MD, PhD; Fang-Fei Wei, MD, PhD; Tine W. Hansen, MD, PhD; Kei Asayama, MD, PhD; Takayoshi Ohkubo, MD, PhD; Jørgen Jeppesen, MD, PhD; Eamon Dolan, MD, PhD; Katarzyna Stolarz-Skrzypek, MD, PhD; Sofia Maljutina, MD, PhD; Edoardo Casiglia, MD, PhD; Lars Lind, MD, PhD; Jan Filipovský, MD, PhD; Gladys E. Maestre, MD, PhD; Yan Li, MD, PhD; Ji-Guang Wang, MD, PhD; Yutaka Imai, MD, PhD; Kalina Kawecka-Jaszcz, MD, PhD; Edgardo Sandoya, MD, PhD; Krzysztof Narkiewicz, MD, PhD; Eoin O'Brien, MD, PhD; Peter Verhamme, MD, PhD; Jan A. Staessen, MD, PhD; for the International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators

**IMPORTANCE** Blood pressure (BP) is a known risk factor for overall mortality and cardiovascular (CV)-specific fatal and nonfatal outcomes. It is uncertain which BP index is most strongly associated with these outcomes.

**OBJECTIVE** To evaluate the association of BP indexes with death and a composite CV event.

**DESIGN, SETTING, AND PARTICIPANTS** Longitudinal population-based cohort study of 11 135 adults from Europe, Asia, and South America with baseline observations collected from May 1988 to May 2010 (last follow-ups, August 2006–October 2016).

**EXPOSURES** Blood pressure measured by an observer or an automated office machine; measured for 24 hours, during the day or the night; and the dipping ratio (nighttime divided by daytime readings).

**MAIN OUTCOMES AND MEASURES** Multivariable-adjusted hazard ratios (HRs) expressed the risk of death or a CV event associated with BP increments of 20/10 mm Hg. Cardiovascular events included CV mortality combined with nonfatal coronary events, heart failure, and stroke. Improvement in model performance was assessed by the change in the area under the curve (AUC).

**RESULTS** Among 11 135 participants (median age, 54.7 years, 49.3% women), 2836 participants died (18.5 per 1000 person-years) and 2049 (13.4 per 1000 person-years) experienced a CV event over a median of 13.8 years of follow-up. Both end points were significantly associated with all single systolic BP indexes ( $P < .001$ ). For nighttime systolic BP level, the HR for total mortality was 1.23 (95% CI, 1.17–1.28) and for CV events, 1.36 (95% CI, 1.30–1.43). For the 24-hour systolic BP level, the HR for total mortality was 1.22 (95% CI, 1.16–1.28) and for CV events, 1.45 (95% CI, 1.37–1.54). With adjustment for any of the other systolic BP indexes, the associations of nighttime and 24-hour systolic BP with the primary outcomes remained statistically significant (HRs ranging from 1.17 [95% CI, 1.10–1.25] to 1.87 [95% CI, 1.62–2.16]). Base models that included single systolic BP indexes yielded an AUC of 0.83 for mortality and 0.84 for the CV outcomes. Adding 24-hour or nighttime systolic BP to base models that included other BP indexes resulted in incremental improvements in the AUC of 0.0013 to 0.0027 for mortality and 0.0031 to 0.0075 for the composite CV outcome. Adding any systolic BP index to models already including nighttime or 24-hour systolic BP did not significantly improve model performance. These findings were consistent for diastolic BP.

**CONCLUSIONS AND RELEVANCE** In this population-based cohort study, higher 24-hour and nighttime blood pressure measurements were significantly associated with greater risks of death and a composite CV outcome, even after adjusting for other office-based or ambulatory blood pressure measurements. Thus, 24-hour and nighttime blood pressure may be considered optimal measurements for estimating CV risk, although statistically, model improvement compared with other blood pressure indexes was small.

JAMA. 2019;322(5):409–420. doi:10.1001/jama.2019.9811

← Editor's Note page 420

+ Supplemental content

+ CME Quiz at [jamanetwork.com/learning](http://jamanetwork.com/learning) and CME Questions page 459

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Group Information:** The International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators appear at the end of the article.

**Corresponding Author:** Jan A. Staessen, MD, PhD, Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Kapucijnenvoer 35, BE-3000 Leuven, Belgium ([jan.staessen@med.kuleuven.be](mailto:jan.staessen@med.kuleuven.be)).

North American,<sup>1,2</sup> European,<sup>3,4</sup> Japanese,<sup>5</sup> and Chinese<sup>6</sup> guidelines unanimously recommend ambulatory blood pressure (BP) monitoring for BP assessment. However, which BP index among the multitude of measurements that can be derived from conventional and ambulatory BP recordings is more closely associated with adverse health outcomes remains unresolved. In several studies, the association between cardiovascular risk and BP was strongest for systolic readings taken at nighttime,<sup>7</sup> an observation subsequently replicated among patients with hypertension<sup>8</sup> or referred for ambulatory BP monitoring.<sup>9</sup> More recently,<sup>10</sup> BP readings via automated office machines was introduced as an alternative to ambulatory monitoring, but the strength of its association with a cardiovascular outcome is unknown. Given the uncertainty left by these previous findings,<sup>7-13</sup> the objective of this study was to evaluate various types of BP measurements and assess the strength of their associations with mortality and adverse cardiovascular outcomes.

## Methods

### Study Participants

All population studies included in the International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcome (IDACO)<sup>14</sup> received ethical approval from the responsible institutional review boards in their country of origin and adhered to the principles of the Declaration of Helsinki.<sup>15</sup> Participants provided written informed consent. The IDACO database was constructed and is regularly updated at the Studies Coordinating Centre in Leuven, but does not include any data allowing identification of study participants. In accordance with current national regulations, review boards either waived or provided ethical clearance for secondary use of data to be included in the IDACO resource.

Population studies qualified for inclusion if office and the ambulatory BP measures and cardiovascular risk factors were available at baseline and if follow-up included both fatal and nonfatal outcomes. The Expanded eMethods section and eTable 1 in Supplement 1 provide detailed information on the population sampling methods, timelines, and country of recruitment. Across all studies, enrollment took place from August 1985 until May 2010 (eTable 1 in Supplement 1). For the current study, baseline refers to the first measurement of the conventional and the ambulatory BP measures along with cardiovascular risk factors (May 1988 until May 2010); timing of the last follow-up ranged from August 2006 to October 2016 across studies. References specifying methods in each of the 13 cohorts are available in the Expanded eMethods section in Supplement 1.

### BP Measurement

Nurses or physicians obtained the conventional readings with a standard mercury sphygmomanometer or with validated auscultatory or oscillometric devices. Patients were considered to have hypertension if their conventional BP was 140/90 mm Hg or higher or if they were taking antihypertensive drugs.

## Key Points

**Question** What is the association of office and ambulatory blood pressure with subsequent risk of mortality and cardiovascular outcomes?

**Findings** In a population-based cohort of 11 135 adults, higher 24-hour and nighttime blood pressure readings were significantly associated with greater risks of death and cardiovascular events that included cardiovascular mortality combined with nonfatal coronary events, heart failure, or stroke. This association persisted after adjusting for other blood pressure measurements taken during an office visit or during ambulatory monitoring.

**Meaning** Higher 24-hour and nighttime blood pressure readings were significantly associated with greater risks of death and a composite of cardiovascular outcomes, although statistically the incremental model improvement was small.

For ambulatory monitoring (eTable 2 in Supplement 1), portable monitors were programmed to obtain ambulatory readings at 30-minute intervals throughout the whole day or at intervals of 15 to 30 minutes during daytime and at intervals ranging from 20 to 60 minutes during the nighttime.<sup>16</sup> Daytime readings ranged from 10 AM to 8 PM in European and South American countries and from 8 AM to 6 PM in Asian countries. The corresponding nighttime intervals ranged from midnight to 6 AM in European and South American countries and from 10 PM to 4 AM in Asian countries. For analysis, ambulatory recordings had to include at least 6 daytime and 3 nighttime readings.<sup>17</sup> We used the mean BP recordings taken by automated devices during the first hour patients were being monitored while in a medical environment. The dipping ratio was calculated by dividing the nighttime by the daytime BP level. We focused on systolic BP, because it is the predominant risk factor among older adults and because the mean age of patients in this study was 53.4 years.<sup>18</sup> Diastolic BP was analyzed to replicate findings for systolic BP. In categorical analyses, the dipping ratios were 0.80 or less for extreme dipping, more than 0.80 to 0.90 or less for normal dipping, more than 0.90 to 1.00 or less for nondipping, and more than 1.00 for reverse dipping.<sup>19</sup> The Expanded Methods section in Supplement 1 describes the collection of questionnaire and biochemical data.

### Ascertainment of End Points

We ascertained vital status and the incidence of fatal and nonfatal events from the appropriate sources in each country.<sup>14</sup> All events were prespecified and coded according to the *International Classification of Diseases (ICD)*.<sup>14</sup> The coprimary end points were total mortality and a composite cardiovascular event consisting of cardiovascular mortality combined with nonfatal coronary events, heart failure, and stroke. Secondary end points included cardiovascular mortality (*ICD-8*, 390-448; *ICD-9*, 390.0-459.9; and *ICD-10*, I00-I79 and R96), coronary events (death from ischemic heart disease [*ICD-8*, 411-412; *ICD-9*, 411 and 414; and *ICD-10*, I20 and I24-I25], sudden death [*ICD-8*, 427.2 and 795; *ICD-9*, 427.5 and 798; and *ICD-10*, I46 and R96], nonfatal myocardial infarction [*ICD-8* or *ICD-9*, 410 and *ICD-10*, I21-I22], and

coronary revascularization), and stroke (*ICD-8* or *ICD-9*, 430-434 and 436; and *ICD-10*, I60-I64 and I67-I68), not including transient ischemic attack. Heart failure (*ICD-8*, 427.0, 427.1, 427.2, 428, 429, 519.1, and 782.4, *ICD-9*, 429, and *ICD-10*, I50 and J81) was included in the composite cardiovascular outcome. Its diagnosis required hospitalization in the Scandinavian cohorts.<sup>20,21</sup> In the other cohorts, heart failure was either a clinical diagnosis or the diagnosis on the death certificate. All outcomes were validated against hospital files or medical records held by primary care physicians or specialists. In all outcome analyses, we only considered the first event within each category. No participant was lost to follow-up.

### Statistical Analysis

We applied the Kolmogorov-Smirnov test for assessing the normality of distributions. For comparison of means and proportions, we applied the large-sample *Z* test and Fisher exact test, respectively. After stratification for cohort and sex, we interpolated missing values of body mass index and serum cholesterol levels from the regression slopes on age. In participants with unknown status of smoking, drinking, antihypertensive treatment, diabetes mellitus, or unknown history of cardiovascular disease, we set the indicator (dummy) variable to the cohort- and sex-specific mean of the codes (0, 1).

We compared the cumulative incidence of the primary and secondary outcomes by dipping status, while adjusting for sex and age, and next for the 24-hour or nighttime BP. In multivariable-adjusted Cox regression, we accounted for cohort (random effect), sex, and baseline characteristics including age, body mass index, smoking and drinking status, serum cholesterol level, antihypertensive drug intake, history of cardiovascular disease, and diabetes mellitus. We expressed hazard ratios (HRs) per increments of 20/10 mm Hg BP and per 0.10-increment in the dipping ratio. In models including 2 BP indexes, we uncorrelated these indexes by regressing one index on the other and using the residual of one index in computing the HRs or in assessing improvement of model performance.<sup>22</sup> We constructed heat maps to visualize the contribution of the 24-hour and nighttime BP measurements in their associations with outcomes. To adjust for cohort, we pooled participants recruited in the framework of the European Project on Genes in Hypertension, Novosibirsk, Russia; Kraków and Gdańsk, Poland; Pilsen, the Czech Republic; and Padova, Italy.<sup>23</sup> We checked the proportional hazards assumption by the Kolmogorov-type supremum test and by testing the interaction between follow-up duration and the BP variables. Sensitivity analyses addressed the use of antihypertensive drug at baseline, the consistency of the results based on a diary approach to define wakefulness and sleep, and the weight of cohorts in the overall pooled results. Improvement in model performance was assessed from change in the area under the curve (AUC).

Dipping status as a categorical variable was analyzed using the deviation from mean coding,<sup>24</sup> which contrasts risk in each group to the average risk in the whole study population and which allows computing confidence intervals for the HR in each group without the need to define a reference group. We did

not apply a correction for multiple testing because the outcomes in our study were highly correlated so that each test did not provide an independent opportunity for a type I error.<sup>25</sup> Thus, the analyses of secondary outcomes should be considered as exploratory. For database management and statistical analysis, we used SAS software, version 9.4, maintenance level 5. Statistical significance was a 2-tailed  $\alpha$  of  $\leq .05$ .

## Results

### Baseline Characteristics of Participants

Of 13 111 people included in the database, we excluded 1976 because they were adolescents without events ( $n = 493$ ) or because they had an ambulatory BP recording with fewer than 6 daytime or 3 nighttime readings ( $n = 1483$ ). The study population analyzed statistically ( $n = 11 135$ ) included 5494 women (49.3%) and consisted of 6929 white Europeans (62.2%), 1887 Asians (17.0%), and 2319 South Americans (20.8%). Missing values were interpolated for body mass index ( $n = 33$ ), serum cholesterol level ( $n = 806$ ), smoking status ( $n = 56$ ), drinking status ( $n = 805$ ), antihypertensive treatment ( $n = 16$ ), diabetes mellitus ( $n = 5$ ), and history of cardiovascular disease ( $n = 1$ ).

The median age at enrollment was 54.7 years (**Table 1**). The study population included 3022 smokers (27.3%) and 5185 participants (56.3%) reporting alcohol consumption. Of 4866 participants (43.7%) with hypertension on conventional BP measurement, 2262 (46.5%) were taking antihypertensive drug treatment. A total of 849 participants (7.6%) had diabetes and 1291 (11.6%) had a history of cardiovascular disease. There were 9286 participants (83.4%) with 3 automated office BP monitoring readings, 1650 (14.8%) with 2, and 199 (1.8%) with 1. The median number of ambulatory readings was 55 (5th-95th percentile intervals, 33-82) for 24-hours, 28 (5th-95th percentile intervals, 14-41) for daytime, and 11 (5th-95th percentile interval, 5-13) for nighttime readings. eTable 3 in **Supplement 1** shows that all BP indexes were highly correlated.

### Primary End Points

#### Incidence of Outcomes

Among 11 135 participants, the median follow-up was 13.8 years (5th-95th percentile interval, 2.5-25.1 years). Across cohorts (eTable 1 in **Supplement 1**), the median follow-up ranged from 2.4 years (5th-95th percentile interval, 2.3-2.6 years) to 22.8 years (5th-95th percentile interval, 11.1-26.2 years). During 153 140 person-years of follow-up, 2836 participants died (18.5 per 1000 person-years) and 2049 experienced a composite cardiovascular event (13.4 per 1000 person-years). eTable 4 in **Supplement 1** lists the number of events by category.

#### Cox Regression

In all outcome analyses that follow, the proportional hazard assumption was not violated and the residual method, as described in the Statistical Analysis section, was used. None of the interaction terms between a BP index under study with any residual of a comparator index reached statistical significance ( $P > .09$ ).

**Table 1. Baseline Characteristics of Participants**

Characteristics	Participants
No. of participants	11 135
Sex, No. (%)	
Men	5641 (50.7)
Women	5494 (49.3)
Region of enrollment, No. (%) <sup>a</sup>	
Europe	6929 (62.2)
Asia	1887 (17.0)
South America	2319 (20.8)
Current smoking, No./total (%) <sup>b,c</sup>	3022/11 079 (27.3)
Drinking alcohol, No./total (%) <sup>b,d</sup>	5815/10 330 (56.3)
Risk factors, No./total (%)	
Hypertension <sup>b,e</sup>	4866 (43.7)
Antihypertensive treatment <sup>b</sup>	2262/11 117 (20.3)
Diabetes mellitus <sup>b,f</sup>	849/11 130 (7.6)
History of CVD <sup>g</sup>	1291/11 134 (11.6)
Dipping status, No. (%) <sup>b,g</sup>	
Extreme	2018 (18.1)
Normal	5617 (50.4)
None	2809 (25.2)
Reverse	691 (6.2)
Age, median (IQR), y	54.7 (41.6-67.3)
BMI, mean (SD)	25.5 (4.4)
No.	11 102
Serum cholesterol, mean (SD), mg/dL	216.3 (45.2)
No.	10 329
Blood pressure, mm Hg <sup>h</sup>	
Conventional	
Systolic/diastolic, mean	132.4/79.8
SD	23.0/11.8
Automated office	
Systolic/diastolic, mean	135.3/82.3
SD	20.0/11.7
24 hours	
Systolic/diastolic, mean	123.6/73.7
SD	14.3/8.5
Daytime	
Systolic/diastolic, mean	129.7/78.7
SD	15.2/9.2
Nighttime	
Systolic/diastolic, mean	112.6/64.7
SD	15.5/9.4
Dipping ratio <sup>i</sup>	
Systolic/diastolic, mean	0.87/0.83
SD	0.08/0.06

Abbreviations: BMI, body mass index, calculated as weight in kilograms divided by height in meters squared; BP, blood pressure; CVD, cardiovascular disease; IQR, interquartile range.

SI conversion factor: to convert cholesterol from mg/dL to mmol/L, multiply by 0.0259; glucose from mg/dL to mmol/L, multiply by 0.0555.

<sup>a</sup> Details provided in eTable 1 in Supplement 1.

<sup>b</sup> Assessed only at baseline.

<sup>c</sup> Use of smoking materials on a daily basis.

<sup>d</sup> Drinking was an average alcohol intake of 5 g or more per day.

<sup>e</sup> A conventional BP of 140/90 mm Hg or higher or use of antihypertensive drugs.

<sup>f</sup> Use of antidiabetic drugs, fasting blood glucose of 126 mg/dL or higher, random blood glucose of 200 mg/dL or higher, a self-reported diagnosis, or diabetes documented in practice or hospital records.

<sup>g</sup> Categorization in extreme dippers ( $\leq 0.80$ ), normal dippers ( $> 0.80$  to  $\leq 0.90$ ), nondippers ( $> 0.90$  to  $\leq 1.00$ ), and reverse dippers ( $> 1.00$ ) was based on the systolic dipping ratio.

<sup>h</sup> Conventional BP was measured using a standard mercury sphygmomanometer or validated auscultatory or oscillometric devices. Automated BP was the average of the ambulatory recordings during the first recording hour, when the monitors were applied in a medical environment. Mean BP levels over the whole day and during day/night (10 AM to 8 PM/midnight to 6 AM for Europeans and South Americans and 8 AM to 6 PM/10 PM to 4 AM in Asians).

<sup>i</sup> The dipping ratio was nighttime divided by daytime BP.

In analyses adjusted for cohort, sex, age, body mass index, smoking and drinking status, serum cholesterol levels, antihypertensive drug treatment use, history of cardiovascular disease and diabetes mellitus (Table 2), the association between systolic BP and the primary outcomes were all statistically significant ( $P < .001$ ). Adjusting for 24-hour systolic BP, the HR for the nighttime systolic BP readings for total mortality was 1.24 (95% CI, 1.14-1.36), and for all

cardiovascular events, the HR was 1.16 (95% CI, 1.05-1.28; Table 2). Adjusting for 24-hour BP readings, the HR for systolic dipping for total mortality was 1.11 (95% CI, 1.06-1.15), and for all cardiovascular outcomes, it was 1.08 (95% CI, 1.03-1.13; Table 2). After adjusting for the nighttime systolic BP, only conventional systolic BP readings was associated with total mortality (HR, 1.05; CI, 1.01 to 1.10;  $P = .02$ ). Adjustment for the nighttime systolic BP did not

**Table 2. Association of Outcomes With Systolic BP Indexes Without or With Adjustment for 24-Hour or Nighttime Systolic BP<sup>a</sup>**

Outcomes	Adjusted		Additionally Adjusted Systolic BP <sup>b</sup>			
	Hazard Ratio (95% CI) <sup>c</sup>	P Value	24 Hours		Nighttime	
			Hazard Ratio (95% CI) <sup>c</sup>	P Value	Hazard Ratio (95% CI) <sup>c</sup>	P Value
<b>Total Mortality (n = 2836)</b>						
Systolic BP index						
Conventional	1.12 (1.08-1.17)	<.001	1.05 (1.01-1.10)	.03	1.05 (1.01-1.10)	.02
Automated office systolic BP	1.08 (1.04-1.12)	<.001	0.97 (0.92-1.02)	.23	1.00 (0.96-1.05)	.94
Measure times						
24 hours	1.22 (1.16-1.28)	<.001	NA	NA	0.98 (0.88-1.08)	.68
Daytime	1.14 (1.09-1.20)	<.001	0.78 (0.69-0.88)	<.001	0.98 (0.92-1.05)	.64
Nighttime	1.23 (1.17-1.28)	<.001	1.24 (1.14-1.36)	<.001	NA	NA
Dipping ratio <sup>d</sup>	1.13 (1.09-1.18)	<.001	1.11 (1.06-1.15)	<.001	1.02 (0.97-1.07)	.46
<b>All Cardiovascular Outcomes (n = 2049)</b>						
Systolic BP index						
Conventional	1.20 (1.15-1.26)	<.001	1.05 (1.00-1.11)	.06	1.09 (1.04-1.14)	.001
Automated office	1.19 (1.14-1.24)	<.001	0.98 (0.93-1.04)	.58	1.07 (1.02-1.12)	.007
Measure times						
24 hours	1.45 (1.37-1.54)	<.001	NA	NA	1.25 (1.11-1.41)	<.001
Daytime	1.33 (1.26-1.41)	<.001	0.77 (0.67-0.89)	<.001	1.11 (1.03-1.20)	.005
Nighttime	1.36 (1.30-1.43)	<.001	1.16 (1.05-1.28)	.004	NA	NA
Dipping ratio <sup>d</sup>	1.14 (1.08-1.19)	<.001	1.08 (1.03-1.13)	<.001	0.92 (0.87-0.98)	.008
<b>Cardiovascular Mortality (n = 1073)</b>						
Systolic BP index						
Conventional	1.22 (1.15-1.29)	<.001	1.07 (1.00-1.15)	.06	1.09 (1.02-1.17)	.008
Automated office	1.19 (1.12-1.26)	<.001	0.97 (0.90-1.05)	.44	1.05 (0.98-1.12)	.14
Measure times						
24 hours	1.48 (1.36-1.60)	<.001	NA	NA	1.17 (1.00-1.37)	.06
Daytime	1.34 (1.24-1.45)	<.001	0.75 (0.62-0.91)	.003	1.09 (0.98-1.20)	.10
Nighttime	1.41 (1.32-1.50)	<.001	1.26 (1.10-1.44)	<.001	NA	NA
Dipping ratio <sup>d</sup>	1.17 (1.10-1.25)	<.001	1.12 (1.05-1.19)	<.001	0.95 (0.88-1.03)	.18
<b>Coronary Outcomes (n = 922)</b>						
Systolic BP index						
Conventional	1.14 (1.07-1.22)	<.001	1.01 (0.94-1.10)	.72	1.04 (0.97-1.12)	.30
Automated office	1.18 (1.11-1.26)	<.001	1.04 (0.95-1.13)	.41	1.08 (1.00-1.16)	.04
Measure times						
24 hours	1.35 (1.24-1.47)	<.001	NA	NA	1.12 (0.94-1.34)	.22
Daytime	1.27 (1.16-1.38)	<.001	0.83 (0.67-1.03)	.09	1.07 (0.96-1.20)	.23
Nighttime	1.30 (1.21-1.40)	<.001	1.20 (1.03-1.40)	.02	NA	NA
Dipping ratio <sup>d</sup>	1.13 (1.05-1.21)	<.001	1.09 (1.01-1.17)	.02	0.95 (0.87-1.04)	.30
<b>Stroke (n = 822)</b>						
Systolic BP index						
Conventional	1.30 (1.21-1.40)	<.001	1.11 (1.02-1.21)	.02	1.16 (1.07-1.26)	<.001
Automated office	1.24 (1.16-1.33)	<.001	0.99 (0.90-1.08)	.76	1.10 (1.02-1.19)	.01
Measure times						
24 hours	1.60 (1.46-1.76)	<.001	NA	NA	1.36 (1.14-1.63)	.001
Daytime	1.45 (1.33-1.58)	<.001	0.80 (0.65-1.00)	.05	1.19 (1.06-1.33)	.003
Nighttime	1.46 (1.36-1.58)	<.001	1.17 (1.01-1.36)	.04	NA	NA
Dipping ratio <sup>d</sup>	1.14 (1.06-1.23)	<.001	1.08 (1.01-1.16)	.03	0.87 (0.80-0.96)	.004

Abbreviations: BP, blood pressure; NA, not applicable.

<sup>a</sup> All models accounted for cohort, sex, age, body mass index, smoking and drinking, serum cholesterol, antihypertensive drug intake, history of cardiovascular disease, and diabetes mellitus.

<sup>b</sup> Models including 2 correlated systolic BP indexes were constructed, using the residual method (see Statistical Analysis section).

<sup>c</sup> Hazard ratios express the risk for increments of 20 mm Hg in systolic BP and 0.10 in the dipping ratio.

<sup>d</sup> The dipping ratio is calculated by dividing nighttime by daytime systolic BP.



**Table 3. Association of Outcomes With 24 Hours or Nighttime Systolic Blood Pressure Adjusted for Other Systolic Blood Pressure Indexes**

Systolic BP Indexes	Systolic BP <sup>a</sup>		Nighttime	
	Hazard Ratio (95% CI) <sup>b</sup>	P Value	Hazard Ratio (95% CI) <sup>b</sup>	P Value
<b>Total Mortality (n = 2836)</b>				
Conventional systolic BP	1.17 (1.10-1.25)	<.001	1.20 (1.14-1.26)	<.001
Automated office systolic BP	1.25 (1.17-1.34)	<.001	1.22 (1.17-1.29)	<.001
<b>Systolic BP</b>				
24 hours	NA	NA	1.24 (1.14-1.36)	<.001
Daytime	1.55 (1.36-1.77)	<.001	1.24 (1.17-1.31)	<.001
Nighttime	0.98 (0.88-1.08)	.68	NA	NA
Dipping ratio <sup>c</sup>	1.19 (1.13-1.26)	<.001	1.21 (1.14-1.28)	<.001
<b>All Cardiovascular Outcomes (n = 2049)</b>				
Conventional systolic BP	1.40 (1.31-1.50)	<.001	1.31 (1.24-1.38)	<.001
Automated office systolic BP	1.47 (1.36-1.59)	<.001	1.32 (1.25-1.40)	<.001
<b>Systolic BP</b>				
24 hours	NA	NA	1.16 (1.05-1.28)	.004
Daytime	1.87 (1.62-2.16)	<.001	1.29 (1.21-1.37)	<.001
Nighttime	1.25 (1.11-1.41)	<.001	NA	NA
Dipping ratio <sup>c</sup>	1.43 (1.34-1.51)	<.001	1.44 (1.35-1.54)	<.001
<b>Cardiovascular Mortality (n = 1073)</b>				
Conventional systolic BP	1.41 (1.28-1.55)	<.001	1.35 (1.26-1.45)	<.001
Automated office systolic BP	1.52 (1.37-1.68)	<.001	1.38 (1.28-1.48)	<.001
<b>Systolic BP</b>				
24 hours	NA	NA	1.26 (1.10-1.44)	<.001
Daytime	1.95 (1.60-2.38)	<.001	1.34 (1.23-1.47)	<.001
Nighttime	1.17 (1.00-1.37)	.06	NA	NA
Dipping ratio <sup>c</sup>	1.44 (1.33-1.56)	<.001	1.46 (1.34-1.59)	<.001
<b>Coronary Outcomes (n = 922)</b>				
Conventional systolic BP	1.33 (1.20-1.48)	<.001	1.28 (1.18-1.39)	<.001
Automated office systolic BP	1.30 (1.16-1.47)	<.001	1.25 (1.15-1.36)	<.001
<b>Systolic BP</b>				
24 h	NA	NA	1.20 (1.03-1.40)	.02
Daytime	1.62 (1.29-2.03)	<.001	1.25 (1.13-1.38)	<.001
Nighttime	1.12 (0.94-1.34)	.22	NA	NA
Dipping ratio <sup>c</sup>	1.32 (1.21-1.44)	<.001	1.35 (1.23-1.48)	<.001
<b>Stroke (n = 822)</b>				
Conventional systolic BP	1.50 (1.34-1.67)	<.001	1.37 (1.26-1.49)	<.001
Automated office systolic BP	1.62 (1.44-1.83)	<.001	1.40 (1.29-1.53)	<.001
<b>Systolic BP</b>				
24 hours	NA	NA	1.17 (1.01-1.36)	.04
Daytime	1.98 (1.58-2.47)	<.001	1.34 (1.21-1.47)	<.001
Nighttime	1.36 (1.14-1.63)	.001	NA	NA
Dipping ratio <sup>c</sup>	1.57 (1.43-1.73)	<.001	1.61 (1.46-1.78)	<.001

Abbreviations: BP, blood pressure; NA, not applicable.

<sup>a</sup> All models accounted for cohort, sex, age, body mass index, smoking and drinking, serum cholesterol, antihypertensive drug intake, history of cardiovascular disease and diabetes mellitus and were constructed, using the residual method (see the Statistical Analysis section).

<sup>b</sup> Hazard ratios express the risk for increments of 20 mm Hg in SBP and 0.10 in the dipping ratio.

<sup>c</sup> The dipping ratio is calculated by dividing nighttime by daytime systolic BP.

remove the statistical significance of the association of the conventional or automated office systolic BP or with the daytime or 24-hour systolic BP with the composite cardiovascular outcomes.

In models including both nighttime and 24-hour systolic BP (Table 3), the HRs for 24-hour measures were 0.98 (95% CI, 0.88-1.08) for total mortality and 1.25 (95% CI, 1.11-1.41) for the composite cardiovascular outcomes. In models that

adjusted for a systolic BP index different from the nighttime systolic BP (Table 3), the HRs expressing the association of the 24-hour systolic BP with the coprimary outcomes ranged from 1.17 (95% CI, 1.10-1.25) to 1.87 (95% CI, 1.62-2.16). After adjusting for each of the other systolic BP indexes (Table 3), the HRs expressing the association of nighttime systolic BP with the coprimary outcomes ranged from 1.16 (95% CI, 1.05-1.28) to 1.44 (95% CI, 1.35-1.54).

### Sensitivity Analyses

The aforementioned findings were generally consistent for diastolic BP (eTables 5 and 6 in [Supplement 1](#)) and in sensitivity analyses—from which 2262 participants (20.3%) taking antihypertensive drug medication at baseline were excluded (eTables 7 and 8 in [Supplement 1](#))—when the diary method was applied to 7133 participants (64.1%) to define periods of wakefulness and sleep (eTables 9 and 10 in [Supplement 1](#)), or when cohorts were excluded (eTable 11 in [Supplement 1](#)).

### Improvement in Model Performance

Based on the results presented in Table 2 and Table 3 for systolic BP and in eTables 5 and 6 in [Supplement 1](#) for diastolic BP, of 30 possible permutations to compare 2 BP indexes, the 24-hour and nighttime measures were carried forward in further analyses to study improvement in model performance.

Heat maps for systolic BP ([Figure 1](#)) showed that along the vertical axis the 10-year risks of both primary outcomes were significantly greater with higher nighttime systolic BP readings ( $P \leq .03$ ), but that along the horizontal axis, the risk of death was not significantly associated with the 24-hour systolic BP ( $P = .66$ ). Heat maps for diastolic BP were confirmatory (eFigure 1 in [Supplement 1](#)).

In general, adding the 24-hour or nighttime systolic BP (eTable 12 in [Supplement 1](#)), or adding 24-hour or nighttime diastolic BP (eTable 13 in [Supplement 1](#)) to models including any other systolic or diastolic BP index significantly improved model performance. Base models that included single systolic BP indexes yielded an AUC of 0.83 for mortality and 0.84 for the cardiovascular outcomes, and adding 24-hour or nighttime systolic BP to base models that included other BP indexes resulted in incremental improvements in AUC of 0.0013 to 0.0027 for total mortality and 0.0031 to 0.0075 for the composite cardiovascular outcome. Adding 24-hour systolic BP to nighttime systolic BP did not significantly improve model performance (eTable 12 in [Supplement 1](#)) with similar findings for 24-hour diastolic BP plus nighttime diastolic BP (eTable 13 in [Supplement 1](#)). Conversely, nighttime systolic or diastolic BP added to 24-hour systolic or diastolic BP improved model performance for the estimation of the 10-year risk of death; the change in the AUC was 0.0013 (95% CI, 0.0001-0.0024) systolic and 0.0012 (95% CI, 0.0002-0.0022) diastolic. Model performance was not significantly improved by adding any other systolic or diastolic BP index to 24-hour or nighttime measures (eTables 14 and 15 in [Supplement 1](#)).

### Dipping as Categorical Variable

Based on systolic BP, the study included 2018 extreme dippers (18.1%), 5617 dippers (50.4%), 2809 nondippers (25.2%), and 691 reverse dippers (6.2%). [Figure 2A](#) and [B](#) show the sex- and age-adjusted cumulative incidence of total mortality and cardiovascular outcomes by dipping status. The sex- and age-adjusted cumulative incidence significantly differed ( $P < .001$ ) according to dipping status with the highest rates in reverse dippers and the lowest rates in extreme dippers. For total mortality, the cumulative 10-year incidence amounted to 3.73% (95% CI, 3.3%-4.16%) for extreme dippers, 4.08% (95% CI, 3.69%-4.47%) in normal dippers, 4.62% (95% CI, 4.13%-

5.12%) in nondippers, and 5.74% (95% CI, 4.92%-6.55%) in reverse dippers; for the composite cardiovascular outcome, these rates were 4.76% (95% CI, 4.16%-5.34%), 5.27% (95% CI, 4.77%-5.78%), 5.87% (95% CI, 5.21%-6.53%), and 7.77% (95% CI, 6.57%-8.95%), respectively. The difference in the sex- and age-adjusted 10-year cumulative incidence between extreme and reverse dippers was 2.01% (95% CI, 1.08%-2.93%;  $P < .001$ ) for total mortality and 3.02% (95% CI, 1.69%-4.34%;  $P < .001$ ) for the composite cardiovascular outcome.

Additional adjustment for the nighttime systolic BP attenuated these differences to 0.33% (95% CI, -0.53% to 1.18%;  $P = .46$ ) and -0.71% (95% CI, -1.83% to 0.41%;  $P = .21$ ), respectively ([Figure 2E](#) and [F](#)), whereas these differences retained significance when adjusted for 24-hour systolic BP: 1.62% (95% CI, 0.74% to 2.50%;  $P < .001$ ) for total mortality and 2.00% (95% CI, 0.80% to 3.19%;  $P = .001$ ) for the composite cardiovascular outcome ([Figure 2C](#) and [D](#)).

### Secondary Outcomes


During follow-up, cardiovascular mortality accounted for 1073 deaths (7.0 per 1000 person-years). Coronary events occurred in 922 participants (6.0 per 1000 person-years) and 822 (5.4 per 1000 person-years) had a stroke (eTable 3 in [Supplement 1](#)). All HRs that associated secondary outcomes with single systolic ( $P < .001$ ) or diastolic ( $P \leq .02$ ) BP indexes were significant (Table 2; eTable 5 in [Supplement 1](#)). Findings for the secondary outcomes were consistent with those for the coprimary outcomes (Table 2 and Table 3 for systolic BP; eTables 5 and 6 for diastolic BP in [Supplement 1](#)). In models including both 24-hour and nighttime BP measures, secondary outcomes were significantly associated with nighttime BP, whereas for 24-hour BP significance was only retained for stroke (Table 2 for systolic BP; eTable 5 for diastolic BP in [Supplement 1](#); HRs for systolic/diastolic 24-hour BP was 1.36 [95% CI, 1.14-1.63]/1.24 [1.06-1.44]). Sensitivity analyses were confirmatory (eTables 7-11 in [Supplement 1](#)). Heat maps for the secondary outcomes and results for improvement in model performance appear in [Figure 1](#) and eTables 12 and 14 for systolic BP and in eFigure 1 and eTables 13 and 15 for diastolic BP. Analyses of the secondary outcomes (eFigure 2 in [Supplement 1](#)) according to dipping status produced results comparable with those of the primary outcomes ([Figure 2](#)).

## Discussion

In this population-based cohort study, higher 24-hour and higher nighttime BP, compared with other BP indexes, were associated with greater risk of all-cause mortality and a composite cardiovascular outcome. These associations remained significant after adjusting for conventional and automated office BP and after adjusting for the daytime BP and dipping ratio or status. These findings were also largely consistent for secondary outcomes and in sensitivity analyses performed to evaluate the influence of antihypertensive drug treatment at baseline, the use of fixed clock-time intervals vs the diary method to define day and night, and the weight of different cohorts in the overall pooled results.




Figure 1. Heat Maps Depicting 10-Year Risk in Relation to 24-Hour and Nighttime Systolic Blood Pressure in 11 135 Study Participants



Derived by Cox proportional hazards regression with 24-hour and nighttime systolic blood pressure (BP) analyzed as continuous variables. Estimates of 10-year risk were standardized to the average of the distributions in the whole study population (mean or ratio) of all covariables. Numbers in the panel A grid represent the percentage of participants within each

systolic BP cross-classification category; numbers in the other grids represent the 10-year risk. See the Results section for P values along horizontal and vertical axes. Risks of total mortality, cardiovascular mortality, and a coronary event were not significantly associated with 24-hour systolic BP ( $P \geq .06$ ).

Figure 2. Cumulative Incidence of Total Mortality and the Composite Cardiovascular Outcomes by Dipping Status



No. of patients						
Dipping status	0	5	10	15	20	25
Reverse	691	569	350	167	78	23
None	2809	2493	1693	1078	445	134
Normal	5617	5163	3833	2717	1047	302
Extreme	2018	1904	1459	1042	457	107

No. of patients						
Dipping status	0	5	10	15	20	25
Reverse	691	529	305	136	60	17
None	2809	2401	1568	981	402	127
Normal	5617	5027	3606	2493	914	272
Extreme	2018	1831	1372	933	385	94

Based on the systolic dipping ratio,  $\leq 0.80$  represents extreme dippers;  $>0.80$  to  $\leq 0.90$ , normal dippers;  $>0.90$  to  $\leq 1.00$ , nondippers; and  $>1.00$ , reverse dippers. Tabulated data are the number of participants at risk by dipping status

at 5-year intervals. P values for trend were derived by Cox proportional hazards regression. The 4 lines in panels E and F are superimposed.

Over the past 30 years, ambulatory BP monitoring developed into the recommended technique for BP measurement.<sup>3,19</sup> The current population-based study confirmed previous research, indicating that ambulatory BP monitoring over and beyond measures taken in clinicians' offices improved risk stratification among patients with<sup>7,8</sup> or those suspected of having hypertension.<sup>9</sup> It strengthened the notion that nighttime BP measures carry valuable prognostic information.<sup>7-9</sup> A meta-

analysis of both summary statistics and individual-level data, combined studies involving patients with hypertension (n = 23 856) separately from those of individuals randomly recruited from populations (n = 9641).<sup>26</sup> In both patients and populations, in analyses in which nighttime BP was additionally adjusted for daytime BP, and vice versa, nighttime BP was a stronger predictor than was daytime BP.<sup>26</sup> With adjustment for the 24-hour BP, both the dipping ratio and dipping status

remained significantly associated with outcome, but as evidenced by the generalized  $R^2$  statistic and in line with the current findings added less than 0.6% to the model fit over and beyond the 24-hour BP readings.<sup>26</sup> Poor reproducibility of the dipping status, intermediate reproducibility of the dipping ratio, and high reproducibility of the nighttime BP might explain the statistically significantly higher predictive value of the nighttime BP.<sup>12,13</sup> Possible explanations for the accuracy of the nighttime BP include minimization of confounding by antihypertensive drug treatment, usually taken in the morning, the standardized conditions during sleep (supine position and absence of movement), and the prognostic value of the basal BP in sedated conditions.<sup>27</sup>

Model performance in the current study was evaluated by change in the AUC. This metric is not very sensitive in model comparisons<sup>28</sup> if the basic model performs well, as was the case in the current study, for which the AUC of the basic model ranged from nearly 0.83 to 0.88 (eTables 12 and 13 in Supplement 1). The prevailing perception among experts is that BP is the strongest modifiable cardiovascular risk factor.<sup>29</sup> The small increments in change in the AUC challenge this concept. Thus, an important issue in the evaluation of an additional risk prediction marker is how to interpret a small AUC increase, which many researchers believe is an imprecise metric because it increases only slightly with the introduction of an additional marker in multivariable-adjusted models, even if the marker under study carries great risk, as reflected by the odds ratio (or HR).<sup>30</sup>

### Limitations

This study has several limitations. First, the diary approach is the gold standard for determining the BP level during wakefulness and sleep.<sup>19</sup> However, the analyses based on short clock-time intervals<sup>16</sup> or confined to 7133 individuals (64.1%) with di-

ary information were confirmatory. Moreover, these short fixed clock-time intervals eliminate the transition periods in the morning and evening when BP changes rapidly, resulting in daytime and nighttime BP levels that are within 1 to 2 mm Hg of the awake and asleep levels.<sup>16</sup> Second, antihypertensive drug treatment was only recorded at baseline and could therefore not be adjusted for as a time-dependent covariable. However, initiation of BP-lowering treatment during follow-up is more likely to weaken rather than to strengthen the associations between baseline BP and outcomes.<sup>7</sup> Third, there might be misclassification bias in the assessment of the cardiovascular study end points.<sup>31</sup> However, all-cause mortality does not require any adjudication, as vital status only involves checking population registries. There was consistency between the findings for total mortality, the composite cardiovascular outcome and the secondary outcomes. Fourth, among some participants, nighttime BP was the time-weighted average of only 3 readings, which is less than proposed by guidelines.<sup>19</sup> However, a recent analysis<sup>17</sup> demonstrated that 6 daytime and 3 nighttime readings are sufficient in large studies to estimate the BP level, to reproducibly cross-classify individuals based on their office and ambulatory BP, and to preserve the association with adverse health outcomes.

### Conclusions

In this population-based cohort study, higher 24-hour and nighttime BP were significantly associated with greater risks of death and a composite cardiovascular outcome, even after adjusting for other office-based or ambulatory blood pressure measurements. Thus, 24-hour and nighttime blood pressure may be considered optimal measurements for estimating cardiovascular risk, although statistically, model improvement compared with other blood pressure indexes was small.

### ARTICLE INFORMATION

**Accepted for Publication:** June 18, 2019.

**Author Affiliations:** Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (Yang, Thijs, Zhang, Wei, Staessen); Department of Cardiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (Yang, Zhang); Laboratorio de Neurociencias and Instituto Cardiovascular, Universidad del Zulia, Maracaibo, Venezuela (Melgarejo, Maestre); Centro de Nefrología and Departamento de Fisiopatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay (Boggia); The Steno Diabetes Center Copenhagen, Gentofte, and Center for Health, Capital Region of Denmark, Copenhagen, Denmark (Hansen); Tohoku Institute for Management of Blood Pressure, Sendai, Japan (Asayama, Ohkubo, Imai); Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (Asayama, Ohkubo); Department of Medicine, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark (Jeppesen); Cambridge University Hospitals, Addenbrook's Hospital, Cambridge, United

Kingdom (Dolan); The First Department of Cardiology, Interventional Electrophysiology and Hypertension, Jagiellonian University Medical College, Krakow, Poland (Stolarz-Skrzypek, Kawecka-Jaszcz); Institute of Internal and Preventive Medicine and Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russian Federation (Malyutina); Department of Medicine, University of Padua, Padua, Italy (Casiglia); Section of Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden (Lind); Faculty of Medicine, Charles University, Pilsen, Czech Republic (Filipovský); Department of Biomedical Sciences, Division of Neuroscience and Department of Human Genetics, University of Texas Rio Grande Valley School of Medicine, Brownsville (Maestre); Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluation, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (Li, Wang); Asociación Española Primera en Salud, Montevideo, Uruguay (Sandoya); Hypertension Unit, Department of Hypertension and Diabetology, Medical University of Gdańsk, Gdańsk, Poland (Narkiewicz); Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland (O'Brien); Centre for

Molecular and Vascular Biology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (Verhamme); Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands (Staessen).

**Author Contributions:** Dr Staessen had full access to the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Concept and design:** Yang, Hansen, Jeppesen, Filipovský, Sandoya, O'Brien, Staessen.

**Acquisition, analysis, or interpretation of data:** Yang, Melgarejo, Thijs, Zhang, Boggia, Wei, Asayama, Ohkubo, Dolan, Stolarz-Skrzypek, Malyutina, Casiglia, Lind, Filipovský, Maestre, Li, Wang, Imai, Kawecka-Jaszcz, Sandoya, Narkiewicz, Verhamme, Staessen.

**Drafting of the manuscript:** Yang, Melgarejo, Sandoya, O'Brien, Staessen.

**Critical revision of the manuscript for important intellectual content:** All authors.

**Statistical analysis:** Yang, Melgarejo, Thijs, Wei, Li, Staessen.

**Obtained funding:** Asayama, Ohkubo, Jeppesen, Casiglia, Maestre, Li, Wang, Narkiewicz, Verhamme, Staessen.

**Administrative, technical, or material support:** Wei, Ohkubo, Stolarz-Skrzypiek, Malyutina, Casiglia, Lind, Maestre, Li, Imai, Sandoya, Narkiewicz, Staessen. **Supervision:** Asayama, Ohkubo, Casiglia, Filipovský, Maestre, Imai, Kawecka-Jaszcz, O'Brien, Verhamme, Staessen.

**Conflict of Interest Disclosures:** Dr Narkiewicz reported receiving lecture fees from Servier, Krka Pharma, Berlin-Chemie/Menarini, Egis, Sandoz, Idorsia, Medtronic, Mylan, Polpharma, Adamed, and Gedeon Richer. No other disclosures were reported.

**Funding/Support:** Belgium: grants HEALTH-F7-305507 HOMAGE from the European Union; advanced researcher grant 2011-294713-EPLORE and proof-of-concept grant 713601-uPROPHET from the European Research Council, JTC2017-046-PROACT from the European Research Area Net for Cardiovascular Diseases; and G.0881.13 from the Research Foundation Flanders, Ministry of the Flemish Community, Brussels, Belgium; *China*: grants 8170245, 81270373, 81470533, and 91639203 from the National Natural Science Foundation of China; 2013CB530700 from the Ministry of Science and Technology; 1012 from the China-European Union Collaboration, Beijing, China; 14ZR1436200 and 15XD1503200 from the Shanghai Commission of Science and Technology; and 20152503 from the Gaofeng Clinical Medicine Education; *Czech Republic*: LSHM-CT-2006-037093 and HEALTH-F4-2007-201550 from the European Union and P36 from Charles University research fund project; *Denmark*: 01-2-9-9A-22914 from the Danish Heart Foundation and R32-A2740 from the Lundbeck Fonden; *Ireland*: the Irish Allied Bank; *Italy*: LSHM-CT-2006-037093 and HEALTH-F4-2007-201550 from the European Union; *Japan*: 16H05243, 16H05263, 16K09472, 16K11850, 16K15359, 17H04126, 17H06533, 17K15853, 17K19930, 18K09674, 18K09904, and 18K17396 from the Ministry of Culture, Sports, Science and Technology; grant-in-aid H28-4 for young scientists of Showa Pharmaceutical University, Japan Atherosclerosis Prevention Fund (comprehensive research on cardiovascular and lifestyle related diseases); H26-Junkankitou (Seisaku)-Ippan-001 and H29-Junkankitou-Ippan-003 from the Ministry of Health, Labor, and Welfare; NouEi 2-02 from the Ministry of Agriculture, Forestry and Fisheries; Academic Contributions from Pfizer Japan Inc; and scholarship donations from Chugai Pharmaceutical Company and Daiichi Sankyo Co; *Poland (Gdańsk)*: LSHM-CT-2006-037093 and HEALTH-F4-2007-201550 from the European Union; *Poland (Kraków)*: LSHM-CT-2006-037093 and HEALTH-F4-2007-201550 from the European Union and Foundation for Polish Science; *Russian Federation*: LSHM-CT-2006-037093 and HEALTH-F4-2007-201550 from the European Union; *Uruguay*: Asociación Española Primera en Salud; *Venezuela*: 1-R01AG036469 A1 from the US National Institute of Aging and the Fogarty International Center, 1-R03 AG054186-01 from the US National Institutes of Health and National Institute of Aging; FONACIT, G-97000726 from Caracas; and LOCTI/008-2008 from FundaConCiencia, Maracaibo.

**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or

approval of the manuscript; and decision to submit the manuscript for publication.

**IDACO Investigators:** *Belgium*: B. Mujaj, N. Cauwenberghs, T. Kuznetsova, L. Thijs, J. A. Staessen, F.-F. Wei, W.-Y. Yang, C.-G. Yu, and Z.-Y. Zhang; *China*: Y. Li, C.-S. Sheng, Q.-F. Huang, and J.-G. Wang; *The Czech Republic*: J. Filipovský, J. Seidlerová, and M. Tichá; *Denmark*: T. W. Hansen, H. Ibsen, J. Jeppesen, S. Rasmussen, and C. Torp-Pedersen; *Ireland*: E. Dolan and E. O'Brien; *Italy*: E. Casiglia, A. Pizzioli, and V. Tikhonoff; *Japan*: K. Asayama, J. Hashimoto, H. Hoshi, Y. Imai, R. Inoue, M. Kikuya, H. Metoki, T. Obara, T. Ohkubo, H. Satoh, and K. Totsune; *Poland (Gdańsk)*: N. Gilis-Malinowska and K. Narkiewicz; *Poland (Kraków)*: A. Adamkiewicz-Piejko, M. Cwynar, J. Gaśowski, T. Grodzicki, K. Kawecka-Jaszcz, W. Lubaszewski, A. Olszanecka, K. Stolarz-Skrzypiek, B. Wizner, W. Wojciechowska, and J. Zyczkowska; *The Russian Federation*: T. Kuznetsova, S. Malyutina, Y. Nikitin, E. Pello, G. Simonova, and M. Voevoda; *Sweden*: B. Andrén, L. Berglund, K. Björklund-Bodegård, L. Lind, and B. Zethelius; *Uruguay*: M. Bianchi, J. Boggia, V. Moreira, E. Sandoya, C. Schettini, E. Schwedt, and H. Senra; *Venezuela*: G. Maestre and J. D. Melgarejo.

**Meeting Presentations:** Part of the results was presented at scientific meetings of the European Society of Cardiology, August 25-30, 2018, Munich, Germany, and of the International Society of Hypertension, September 20-23, 2018, Beijing, China.

**Additional Contributions:** We thank V. De Leebeek, MSc, and R. Wolfs, BSc, Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium, for clerical assistance. They received a salary from the University of Leuven, but no additional compensation for this work.

**Data Sharing Statement:** See Supplement 2.

## REFERENCES

- Leung AA, Nerenberg K, Daskalopoulou SS, et al; CHEP Guidelines Task Force. Hypertension Canada's 2016 Canadian Hypertension Education Program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. *Can J Cardiol*. 2016;32(5):569-588. doi:10.1016/j.cjca.2016.02.066
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA guideline for prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2018;71(19):e127-e248. doi:10.1016/j.jacc.2017.11.006
- National Institute for Health and Clinical Excellence (NICE). Hypertension in adults: diagnosis and management. <http://www.nice.org.uk/guidance/CG127>. Published August 2011. Updated November 2016. Accessed June 3, 2019.
- Williams B, Mancia G, Spiering W, et al; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*. 2018;39(33):3021-3104. doi:10.1093/eurheartj/ehy339

- Shimamoto K, Ando K, Fujita T, et al; Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014). *Hypertens Res*. 2014;37(4):253-390. doi:10.1038/hr.2014.20
- Liu LS. Writing Group of 2010 Chinese guidelines for the management of hypertension. 2010 Chinese guidelines for the management of hypertension [in Chinese]. *Chin J Hypertens*. 2011;19(8):701-742.
- Staessen JA, Thijs L, Fagard R, et al; Systolic Hypertension in Europe Trial Investigators. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. *JAMA*. 1999;282(6):539-546. doi:10.1001/jama.282.6.539
- Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. *Hypertension*. 2005;46(1):156-161. doi:10.1161/01.HYP.0000170138.56903.7a
- Ben-Dov IZ, Kark JD, Ben-Ishay D, Mekler J, Ben-Arie L, Bursztyn M. Predictors of all-cause mortality in clinical ambulatory monitoring: unique aspects of blood pressure during sleep. *Hypertension*. 2007;49(6):1235-1241. doi:10.1161/HYPERTENSIONAHA.107.087262
- Myers MG, Valdivieso M, Kiss A. Use of automated office blood pressure measurement to reduce the white coat response. *J Hypertens*. 2009;27(2):280-286. doi:10.1097/HJH.0b013e32831b9e6b
- O'Brien E, Sheridan J, O'Malley K. Dippers and non-dippers. *Lancet*. 1988;2(8607):397. doi:10.1016/S0140-6736(88)92867-X
- Hernández-del Rey R, Martín-Baranera M, Sobrino J, et al; Spanish Society of Hypertension Ambulatory Blood Pressure Monitoring Registry Investigators. Reproducibility of the circadian blood pressure pattern in 24-h versus 48-h recordings: the Spanish Ambulatory Blood Pressure Monitoring Registry. *J Hypertens*. 2007;25(12):2406-2412. doi:10.1097/HJH.0b013e3282effd1
- McGowan NJ, Gough K, Padfield PL. Nocturnal dipping is reproducible in the long term. *Blood Press Monit*. 2009;14(5):185-189. doi:10.1097/MBP.0b013e328328ff4e1
- Thijs L, Hansen TW, Kikuya M, et al; IDACO Investigators. The International Database of Ambulatory Blood Pressure in relation to Cardiovascular Outcome (IDACO): protocol and research perspectives. *Blood Press Monit*. 2007;12(4):255-262. doi:10.1097/MBP.0b013e3280f813bc
- World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA*. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053
- Fagard R, Brguljan J, Thijs L, Staessen J. Prediction of the actual awake and asleep blood pressures by various methods of 24 h pressure analysis. *J Hypertens*. 1996;14(5):557-563. doi:10.1097/00004872-199605000-00003
- Yang WY, Thijs L, Zhang ZY, et al; International Database on Ambulatory blood pressure in relation to Cardiovascular Outcomes (IDACO) Investigators. Evidence-based proposal for the number of ambulatory readings required for assessing blood



pressure level in research settings: an analysis of the IDACO database. *Blood Press*. 2018;27(6):341-350. doi:10.1080/08037051.2018.1476057

18. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? the Framingham Heart Study. *Circulation*. 2001;103(9):1245-1249. doi:10.1161/01.CIR.103.9.1245

19. O'Brien E, Parati G, Stergiou G, et al; European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. *J Hypertens*. 2013;31(9):1731-1768. doi:10.1097/HJH.0b013e328363e964

20. Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C. Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population based study. *Am J Hypertens*. 2006;19(3):243-250. doi:10.1016/j.amjhyper.2005.09.018

21. Ingelsson E, Björklund-Bodegård K, Lind L, Arnlöv J, Sundström J. Diurnal blood pressure pattern and risk of congestive heart failure. *JAMA*. 2006;295(24):2859-2866. doi:10.1001/jama.295.24.2859

22. Pencina MJ, D'Agostino RB, Zdrojewski T, et al. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. *Eur J Prev Cardiol*. 2015;22(10):1321-1327. doi:10.1177/2047487315569411

23. Kuznetsova T, Staessen JA, Kawecka-Jaszcz K, et al. Quality control of the blood pressure phenotype in the European Project on Genes in Hypertension. *Blood Press Monit*. 2002;7(4):215-224. doi:10.1097/00126097-200208000-00003

24. Hosmer DW Jr, Lemeshow S. *Applied Logistic Regression*. New York, NY: John Wiley & Sons; 1989: 47-56.

25. Nyholt DR. Genetic case-control association studies—correcting for multiple testing. *Hum Genet*. 2001;109(5):564-567. doi:10.1007/s00439-001-0611-4

26. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure. *Hypertension*. 2011;57(1):3-10. doi:10.1161/HYPERTENSIONAHA.109.133900

27. Smirk FH. Observations on mortality of 270 treated and 199 untreated retinal grade I and II hypertensive patients followed in all instances for 5 years. *N Z Med J*. 1964;63:413-443.

28. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. *Circulation*. 2007;115(7):928-935. doi:10.1161/CIRCULATIONAHA.106.672402

29. Murray CJL, Ezzati M, Flaxman AD, et al. GBD 2010: design, definitions, and metrics. *Lancet*. 2012;380(9859):2063-2066. doi:10.1016/S0140-6736(12)61899-6

30. Baker SG, Schuit E, Steyerberg EW, et al. How to interpret a small increase in AUC with an additional risk prediction marker: decision analysis comes through. *Stat Med*. 2014;33(22):3946-3959. doi:10.1002/sim.6195

31. Mieno MN, Tanaka N, Arai T, et al. Accuracy of death certificates and assessment of factors for misclassification of underlying cause of death. *J Epidemiol*. 2016;26(4):191-198. doi:10.2188/jea.JE20150010

## Editor's Note

# Effective Use of Ambulatory Blood Pressure Monitoring

Philip Greenland, MD

**For almost 100 years**, higher levels of blood pressure (BP) have been recognized as critically important risk factors for clinical disorders of the cardiovascular systems, brain, and kidney.<sup>1</sup> With numerous effective lifestyle and drug



Related article [page 409](#)

treatments available and with clinical trials that convincingly showed the benefits of BP lowering in appropriately selected patients, it is now widely recommended that BP measurement be a routine part of general health screening.<sup>1-6</sup> Evidence favoring the use of ambulatory BP monitoring (ABPM) for measurement of BP has accumulated and guidelines now refer to ABPM as the “best out-of-office measurement method.”<sup>1</sup> In addition, the Centers for Medicare & Medicaid Services (CMS) recently proposed to pay for expanded use of ABPM for detection of suspected “white coat” hypertension and detection of masked hypertension.<sup>7</sup>

Ambulatory BP monitoring is used to obtain out-of-office BP readings at established intervals, usually every 15 to 30 minutes over a period of at least 24 hours. A systematic review conducted by the US Preventive Services Task Force<sup>8</sup> concluded that ABPM provided a better method to predict long-term cardiovascular disease outcomes than did office BP measurements. Therefore, as described in the article by Yang and colleagues,<sup>9</sup> ABPM is considered a pre-

ferred method for BP assessment in North American, European, Japanese, and Chinese guidelines.<sup>1-6</sup> However, because ABPM monitoring generates a much larger volume of data than other types of BP measurement, including nighttime BP measurements, it has been uncertain which BP index, or indexes, are more strongly associated with adverse health outcomes. The goal of the study by Yang et al<sup>9</sup> was to examine data from numerous sources to address this clinically important question.

Using a rigorous assessment of ABPM in more than 11 000 adults, higher 24-hour and nighttime BP were significantly associated with greater risks of death and a cardiovascular outcome, consisting of cardiovascular mortality combined with nonfatal coronary events, heart failure, and stroke. The association persisted after adjusting for other office-based or ambulatory monitoring-derived BP measurements, all of which were also associated with the adverse outcomes. This is important information for patients and clinicians as they determine how to use the large amount of BP data from ABPM. Based on these findings, it is reasonable to consider the 2 most clinically relevant measurements from ABPM to be the 24-hour BP and the nighttime BP. Either could be used to justify treatment of BP that is above the treatment threshold. Most important is to obtain accurate measurement from every patient and to initiate and monitor treatment when indicated.